Advice - reimburse lisocabtagene maraleucel (Breyanzi®) for the treatment of lymphoma
The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse lisocabtagene maraleucel (Breyanzi®, liso-cel) from the basic health care package after price negotiations. This medicinal product can be used for certain patients with lymphoma. The reason for this advice was the placement of the medicinal product in the lock procedure’ for expensive medicinal products.
Current state of affairs: advisory report sent to the Minister
The National Health Care Institute has sent this advice to the Minister of VWS. The Minister makes the final decision whether or not to reimburse the medicinal product from the basic health care package.
Liso-cel is intended for certain people with lymphoma
Liso-cel is the active substance. The brand name is Breyanzi®. The medicinal product is a single injection.
This medicinal product can be used in patients with an aggressive form of lymphoma. The manufacturer has requested reimbursement for adult patients with diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and Grade 3B follicular lymphoma (FL3B). DLBCL is a form of lymphoma. These are patients who have relapsed or are refractory within 12 months of completion of primary care chemo-immunotherapy. Relapsing means that the cancer has come back after it was partially or completely gone. Refractory means that the tumour did not respond to earlier treatment.
Advice from the National Health Care Institute on the reimbursement of liso-cel
The National Health Care Institute advises the Minister of Health, Welfare and Sport to reimburse liso-cel (Breyanzi®) from the basic health care package after price negotiations. The net price of liso-cel after the price negotiations cannot exceed the net price of the standard treatment with axi-cel.
More information or questions?
If you have any questions about this advice, please send your question to the National Health Care Institute via warcg@zinl.nl. If you have questions about the reimbursement of a medicine, the insurance excess or whether you need to pay a personal contribution, please ask your health insurance provider.
How did the advice come about?
The National Health Care Institute advises the Minister on issuing a package recommendation. The Minister makes the final decision whether or not to reimburse the medication from the basic health care package.
Lock procedure for expensive medicinal products
The Minister has placed liso-cel for this indication in the lock procedure for expensive medicinal products. A medicinal product in this lock procedure will not be eligible for reimbursement from the basic health care package until:
- there is a positive package advice from the National Health Care Institute;
- there are arrangements and safeguards for appropriateness in place;
- price reductions have been successfully negotiated with the manufacturer.
For more information, see the page ‘Lock procedure for expensive medicinal products’.